ArticleBMJ (Clinical research ed.)2011
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
Article in BMJ (Clinical research ed.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2018Pooled it
- Combined oral contraceptives: venous thrombosis.The Cochrane database of systematic reviews · 2014Pooled it
- Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2013Pooled it
- Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.Drug safety · 2012Pooled it
- Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.The journal of family planning and reproductive health care · 2012Trial
- Combined oral contraceptives alter ectonucleotidase and adenosine deaminase activities in peripheral blood cells.Purinergic signalling · 2025Article
- Modern sources of controls in case-control studies.American journal of epidemiology · 2025Article
- Spironolactone use for acne is not associated with an increased risk of venous thromboembolism: A matched, retrospective cohort study.Journal of the American Academy of Dermatology · 2023Article
- Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management.American journal of clinical dermatology · 2023Review
- High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro.PloS one · 2023Article
- Association between oral contraceptive use and incident heart failure.ESC heart failure · 2021Article
- Contraception in chronic kidney disease: a best practice position statement by the Kidney and Pregnancy Group of the Italian Society of Nephrology.Journal of nephrology · 2020Article
- Women's health inBMJ open · 2020Observational
- Do Norwegian providers comply with national recommendations when prescribing combined oral contraceptives to starters? A cohort study.BMJ open · 2019Article
- Comparison of Fusion Rates Based on Graft Material Following Occipitocervical and Atlantoaxial Arthrodesis in Adults and Children.Operative neurosurgery (Hagerstown, Md.) · 2018Article
- Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database.JAMA internal medicine · 2018Article
- The incidence and prognosis of thromboembolism associated with oral contraceptives: Age-dependent difference in Japanese population.The journal of obstetrics and gynaecology research · 2018Article
- Comprehensive review of cardiovascular toxicity of drugs and related agents.Medicinal research reviews · 2018Review
- The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases.Intestinal research · 2018Article
- Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.Drug safety · 2017Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel.
designNested case-control and cohort study.
settingThe study was based on information from PharMetrics, a United States based company that collects information on claims paid by managed care plans.
participantsThe study encompassed all women aged 15 to 44 years who received an oral contraceptive containing either drospirenone or levonorgestrel after 1 January 2002. Cases were women with current use of a study oral contraceptive and a diagnosis of venous thromboembolism in the absence of identifiable clinical risk factors (idiopathic venous thromboembolism). Up to four controls were matched to each case by age and calendar time.
main outcome measuresOdds ratios comparing the risk of non-fatal venous thromboembolism in users of the two contraceptives; incidence rates and rate ratios of non-fatal venous thromboembolism for users of each of the study contraceptives.
results186 newly diagnosed, idiopathic cases of venous thromboembolism were identified in the study population and matched with 681 controls. In the case-control analysis, the conditional odds ratio for venous thromboembolism comparing use of oral contraceptives containing drospirenone with use of those containing levonorgestrel was 2.3 (95% confidence interval 1.6 to 3.2). The incidence rates for venous thromboembolism in the study population were 30.8 (95% confidence interval 25.6 to 36.8) per 100,000 woman years among users of oral contraceptives containing drospirenone and 12.5 (9.61 to 15.9) per 100,000 woman years among users of oral contraceptives containing levonorgestrel. The age adjusted incidence rate ratio for venous thromboembolism for current use of oral contraceptives containing drospirenone compared with those containing levonorgestrel was 2.8 (2.1 to 3.8).
conclusionsThe risk of non-fatal venous thromboembolism among users of oral contraceptives containing drospirenone seems to be around twice that of users of oral contraceptives containing levonorgestrel, after the effects of potential confounders and prescribing biases have been taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.